New role for azathioprine in case of switching anti-TNFs in IBD
- PMID: 32075889
- DOI: 10.1136/gutjnl-2020-320677
New role for azathioprine in case of switching anti-TNFs in IBD
Keywords: azathioprine; crohn's disease; inflammatory bowel disease; infliximab; ulcerative colitis.
Conflict of interest statement
Competing interests: KP: received a lecture fee from Mitsubishi Tanabe Pharma; ASC: received consultancy fees from AbbVie, Janssen, Takeda, Miraca, Ferring, AMAG and Pfizer; PMI has received honoraria for acting in an advisory capacity for or talking on behalf of AbbVie, Arena, Celgene, Falk Pharma, Ferring, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Prometheus, Roche, Takeda, Tillotts, Topivert, Sapphire Medical, Sandoz, Shire, VH2, Vifor Pharma, Warner Chilcott, and has received research support from MSD, Takeda and Pfizer.
Comment on
-
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.Gut. 2020 Jul;69(7):1206-1212. doi: 10.1136/gutjnl-2019-319758. Epub 2020 Jan 24. Gut. 2020. PMID: 31980448 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical